Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorvardur R Halfdanarson

Showing results (111-120 of 213) with videos related to

Pageof 22
Sort By:
AJR. American Journal of Roentgenology|February 8, 2023
Imaging of Small-Bowel Neuroendocrine Neoplasms: <i>AJR</i> Expert Panel Narrative ReviewPatrick J Navin, Eric C Ehman, Jason B Liu, et al.
The Oncologist|January 26, 2019
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)Thorvardur R Halfdanarson, Nathan R Foster, George P Kim, et al.
JAMA Network Open|February 22, 2023
Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line PembrolizumabBahar Saberzadeh-Ardestani, Jeremy C Jones, Joleen M Hubbard, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 16, 2025
Incidence and risk of gastric neuroendocrine tumors and adenocarcinoma in patients with atrophic gastritis/pernicious anemiaRachel V Christenson, Hala Muaddi, Emily Siegler, et al.
American Journal of Surgery|September 3, 2020
Comparison of benign and malignant insulinomaAlaa Sada, Thomas Szabo Yamashita, Amy E Glasgow, et al.
Frontiers in Nuclear Medicine|December 12, 2024
Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypesLaura C Jorgenson, Michael S Torbenson, Thorvardur R Halfdanarson, et al.
Journal of the American College of Surgeons|June 25, 2022
Comparison Between Sporadic and Multiple Endocrine Neoplasia Type 1-Associated InsulinomaAlaa Sada, Elizabeth B Habermann, Thomas Szabo Yamashita, et al.
American Journal of Clinical Oncology|March 18, 2014
The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung CancerTaher Abu-Hejleh, Elizabeth A Chrischilles, Thorvardur R Halfdanarson, et al.
Theranostics|April 22, 2024
Theranostics and artificial intelligence: new frontiers in personalized medicineGokce Belge Bilgin, Cem Bilgin, Brian J Burkett, et al.
JCO Precision Oncology|July 8, 2024
Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective StudyYael Kusne, Terra Lasho, Christy Finke, et al.
Pageof 22

Showing results (111-120 of 213) with videos related to

Sort By:
Pageof 22
AJR. American Journal of Roentgenology|February 8, 2023
Imaging of Small-Bowel Neuroendocrine Neoplasms: <i>AJR</i> Expert Panel Narrative ReviewPatrick J Navin, Eric C Ehman, Jason B Liu, et al.
The Oncologist|January 26, 2019
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)Thorvardur R Halfdanarson, Nathan R Foster, George P Kim, et al.
JAMA Network Open|February 22, 2023
Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line PembrolizumabBahar Saberzadeh-Ardestani, Jeremy C Jones, Joleen M Hubbard, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 16, 2025
Incidence and risk of gastric neuroendocrine tumors and adenocarcinoma in patients with atrophic gastritis/pernicious anemiaRachel V Christenson, Hala Muaddi, Emily Siegler, et al.
American Journal of Surgery|September 3, 2020
Comparison of benign and malignant insulinomaAlaa Sada, Thomas Szabo Yamashita, Amy E Glasgow, et al.
Frontiers in Nuclear Medicine|December 12, 2024
Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypesLaura C Jorgenson, Michael S Torbenson, Thorvardur R Halfdanarson, et al.
Journal of the American College of Surgeons|June 25, 2022
Comparison Between Sporadic and Multiple Endocrine Neoplasia Type 1-Associated InsulinomaAlaa Sada, Elizabeth B Habermann, Thomas Szabo Yamashita, et al.
American Journal of Clinical Oncology|March 18, 2014
The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung CancerTaher Abu-Hejleh, Elizabeth A Chrischilles, Thorvardur R Halfdanarson, et al.
Theranostics|April 22, 2024
Theranostics and artificial intelligence: new frontiers in personalized medicineGokce Belge Bilgin, Cem Bilgin, Brian J Burkett, et al.
JCO Precision Oncology|July 8, 2024
Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective StudyYael Kusne, Terra Lasho, Christy Finke, et al.
Pageof 22